Skip to main content
Fig. 5 | Molecular Neurodegeneration

Fig. 5

From: A brain-targeted, modified neurosin (kallikrein-6) reduces α-synuclein accumulation in a mouse model of multiple system atrophy

Fig. 5

Delivery of LV-NR-R80Q-apoB reduces the propagation of α-syn to astrocytes and clearance via microglia in MBP-α-syn tg mice. Vibratome brain sections from the non-tg and MBP-α-syn tg that received i.p. injections of LV-Control or LV-NR-R80Q-apoB were double immunofluorescence labeled with antibodies against cellular markers and human α-syn and analyzed with the laser scanning confocal microscope with an optical image of 1 μm with fluorescent signals in co-registry. Dotted box to the left depicts the image field zoomed represented under detail. a Double immunolabeling for the astrocyte marker S100 (red) and human α-syn (green) with nuclei (DAPI, blue). Co-immunolabeling is represented by signal in yellow. b Computer aided image analysis of the % of S100 cells displaying α-syn immunofluorescence in the corpus callosum and striatum. c Double immunolabeling for the microglial marker Iba-1 (red) and human α-syn (green) with nuclei (DAPI, blue). Co-immunolabeling is represented by signal in yellow. d Computer aided image analysis of the % of Iba-1 cells displaying α-syn immunofluorescence in the corpus callosum and striatum. n = 10 mice per group 9–10 m/o at the end of the treatment. Scale bar = 10 μm, detail = 20 μm. # indicates statistical significance (p < 0.05, one way ANOVA, post hoc Tukey-Kramer) compared to LV-Control treated MBP-α-syn tg mice

Back to article page